Intrahepatic cholangiocarcinoma (IHCC) is a much-overlooked cancer with a mortality rate that has increased throughout recent years, as stated by the American Cancer Society . In the United States alone, there are an estimated 8,000 adults being diagnosed with IHCC every year, with a five-year survival rate of 9% . Chemotherapy options for the treatment of IHCC include systemic chemotherapy such as gemcitabine, capecitabine, and oxaliplatin. These medications carry a wide array of adverse factors that may warrant discontinuation due to the detriment to the well-being of the patient. Additionally, a broad field of therapy that may also be used, even throughout many other types of cancers, is aimed to arm the immune system, such as targeted therapy as well as immunotherapy. Even with the consideration of these options, we cannot say that our issue has been solved. If the cancer is diagnosed at an early stage and treated adequately, the five-year survival rate is still at 24% , which will still result in the mortality of majority of the individuals with IHCC. Therefore, the discovery of new potential molecular targets is required which could be used in rationale designing of the prevention and treatment strategies against advanced IHCC. The ribosome biogenesis process is dysregulated in most cancer cells because of the high demand of protein synthesis. However, the role of ribosome biogenesis components was the least studied in cancer settings. From our extensive research in various systems, we found that POLR1A (RPA194), a catalytic subunit of RNA polymerase I, is significantly overexpressed (P
Bangash, Muhammad A.; Bangash, Aun A.; Ahsan, Haider; Alvi, Sahir; Ahmad, Mudassier; Rincon, Alejandro; Owusu-Mireku, Samuel; and Hafeez, Bilal, "Significance of Targeting RNA Polymerase I in Intrahepatic Cholangiocarcinoma" (2023). MEDI 9331 Scholarly Activities Clinical Years. 76.
Immunology and Microbiology